Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids.
Zeng PM, Sun XY, Li Y et al. · Stem cell reports · PMID 40816274
Study summary
Main finding
Full-length thymosin beta4 treatment improved neuronal-development measures and reduced amyloid-related abnormalities in familial-disease organoids. The authors also reported effects in a mouse disease model.
Human stem-cell-derived brain organoids and 5xfAD mice
How the study was set up
Familial Alzheimer-related brain organoids made from induced stem cells and an Alzheimer mouse model were studied, alongside analyses of human neuronal gene expression.
What the researchers measured
Neuron maturation, cell senescence, amyloid production, and thymosin beta4-related changes were examined.
How to read this evidence
Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.
Results in context
Organoids and mice showed changes after thymosin beta4 exposure. The patient-data component concerned gene expression, and the paper does not demonstrate clinical treatment of Alzheimer disease.
What this does not establish
Human organoids are laboratory models, not treated patients. This paper studies thymosin beta4 and does not establish TB-500 equivalence or Alzheimer disease treatment in people.
This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.
Publication & source
Why this paper is included
The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.
Publication indexing
Journal Article · Research Support, Non-U.S. Gov't